Blinatumomab (Blincyto)
Jump to navigation
Jump to search
Mechanism of action
Bi-specific T-cell engager (BiTE) that targets CD19.
Diseases for which it is used
History of changes in FDA indication
- 7/1/2014: Granted FDA breakthrough therapy designation "for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)."
Also known as
MT103